On July 10, 2024, Senti Biosciences, Inc. held its 2024 Annual Meeting of Stockholders where several key proposals were voted upon. The stockholders approved an amendment to the company's Second Amended and Restated Certificate of Incorporation to limit the liability of certain officers, known as the Officer Exculpation Amendment. This amendment aligns with recent changes to Delaware law and was previously approved by the Board of Directors, contingent on stockholder approval. Additionally, stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. Another significant amendment approved was to effect a reverse stock split of the company's common stock at a ratio to be determined by the Board, within a range from...Show More

On July 10, 2024, Senti Biosciences, Inc. held its 2024 Annual Meeting of Stockholders where several key proposals were voted upon. The stockholders approved an amendment to the company's Second Amended and Restated Certificate of Incorporation to limit the liability of certain officers, known as the Officer Exculpation Amendment. This amendment aligns with recent changes to Delaware law and was previously approved by the Board of Directors, contingent on stockholder approval. Additionally, stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. Another significant amendment approved was to effect a reverse stock split of the company's common stock at a ratio to be determined by the Board, within a range from 1-for-5 to 1-for-30. The Officer Exculpation Amendment became effective upon its filing with the Secretary of State of Delaware on the date of the Annual Meeting. The meeting saw a turnout of 68.97% of the total number of shares entitled to vote, with the final voting results confirming the approval of the proposed amendments.